Southbound left lane of NSE near Menora Tunnel reopens after landslide, say Perak cops
NiveshIQ
NSE: STAR · Pharma
Strides Pharma Science Ltd.
₹1,183.40▼ ₹33.60 (-2.76%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on STAR. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Strides Pharma Science Ltd.
Strides Pharma Science Limited (STAR) is a leading Indian pharmaceutical company with a strong presence in North America, Australia, Africa, Europe, and Asia. The company's core business revolves around the development, manufacturing, and marketing of generic finished dosage formulations, therapeutic products, and branded generics. Its product portfolio includes antivirals, antibiotics, NSAIDs, and allergy treatment, among others. Strides Pharma Science Limited has a significant market share in the Indian pharmaceutical industry and is known for its high-quality products. The company has a strong distribution network and a diverse product portfolio, which has enabled it to maintain a competitive edge in the market. With a revenue of ₹5004 Cr and net income of ₹613 Cr, the company has demon
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,979 Cr +115.00% | ₹4,565 Cr +14.70% | ₹4,859 Cr +6.40% |
| EBITDA Margin | 13.65% | 17.78% | 22.15% |
| Net Profit | -2.10% | ₹3,622 Cr -3953.10% | ₹600.89 Cr -83.40% |
| EPS | ₹-7.95 | ₹390.95 | ₹60.34 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Strides Pharma Science receives USFDA Form 483 following facility inspection
Slope collapse causes 15km-long jam on NSE near Ipoh
🔒
+ 3 more stories about Strides Pharma Science Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 265 Cr, PAT ₹165 Cr, EPS ₹17.02, EBITDA margin 18.5%. Growth context: revenue QoQ -4.4%, PAT QoQ +28.3%.
Management commentary highlights product launches, approvals, and therapy-mix improvement as key drivers of near-term gr...
FY26 (last completed FY): revenue ₹4, 859 Cr, PAT ₹601 Cr, EBITDA margin 22.1%, EPS ₹60.34. Year-on-year: revenue YoY +6...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for STAR
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track STAR alongside your other holdings
Unlock full STAR research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Strides Pharma Science Ltd.?
NiveshIQ detects active intelligence signals for Strides Pharma Science Ltd. (STAR) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Strides Pharma Science Ltd.?
Strides Pharma Science Ltd. operates in the Pharma sector with a market capitalisation of ₹1,077,499.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.